Evolving Evidence for CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma

This segment reviews how clinical trial findings and real-world experience have strengthened the role of CAR T-cell therapy in relapsed or refractory multiple myeloma. Dr. Raje describes the major advancements demonstrated by BCMA directed CAR T products, which have shown high response rates, deep remissions, and impressive durability in pivotal studies. These therapies have produced responses approaching 100 percent in some settings, highlighting their effectiveness for patients with advanced disease. Real world experience has reinforced these outcomes, with observed efficacy and safety closely mirroring clinical trial data, which is uncommon for complex cellular therapies. This alignment across evidence sources has increased confidence in the long-term potential of CAR T therapy and supports its use earlier in the treatment sequence. The discussion emphasizes that improved durability, consistent real-world performance, and expanding clinical data have collectively positioned CAR T-cell therapy as a transformative option in multiple myeloma care.